XtalPi Partners with Biopharma Company to Develop Oral Small Molecule Therapeutics
XtalPi has entered a strategic partnership with an international biopharmaceutical company to develop oral small molecule therapeutics targeting a GPCR receptor, with a potential deal value exceeding $400 million.